Then, database systematic survey and differential methylated regions (DMR) analysis were performed, which demonstrated that a novel hypermethylated zinc finger‐containing protein, THAP10, is a target gene and can be epigenetically suppressed by AML1‐ETO at the transcriptional level in t(8;21) AML, and suppression of THAP10 predicts a poor clinical outcome. The gene discussed is RUNX1; the disease is acute myeloid leukemia.